The prevalence of methylenetetrahydrofolate reductase 677 C-T, factor v 1691 G-A, and prothrombin 20210 G-A mutations in healthy populations in sétif, Algeria

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 5, 2009, Pages 529-534

  Bourouba, Romyla ^a   Houcher, Bakhouche ^b   Djabi, Farida ^c   Eǧin, Yonca ^d   Akar, Nejat ^d  

^a UNIVERSITY OF BATNA   (Algeria)

^b Faculty of Sciences   (Morocco)

^c FERHAT ABBAS UNIVERSITY   (Algeria)

^d ANKARA UNIVERSITY   (Turkey)

Author keywords

Algeria; Factor V; Methylenetetrahydrofolate reductase; Prothrombin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; PROTHROMBIN;

ADULT; ALGERIA; ARTICLE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THROMBOPHILIA;

ADULT; ALGERIA; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; YOUNG ADULT;

EID: 70449686956     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608319944     Document Type: Article

References (54)

1. Bertina RM, Koeleman BPC, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 ; 369: 64-67.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM A common genetic variation in the 3gs-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996 ; 88: 3698-3703.
3. Couturaud F., Oger E., Abalain JH, et al. Methylenetetrahydrofolate reductase C677T genotype and venous thrombo-embolic disease. Respiration. 2000 ; 67: 657-661.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, OgsFallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998 ; 158: 585-593.
5. Hagstrom JN, Walter J., Bluebond-Langner R., Amatniek JC, Manno CS, High KA Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr. 1998 ; 133: 777-781.
6. Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J., Clegg JB Born to clot: the European burden. Br J Haematol. 1999 ; 105: 564-566.
7. Hira B., Pegoraro RJ, Rom L., Moodley J. Absence of factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with pre-eclampsia and eclampsia. BJOG. 2003 ; 110: 327-328.
8. Abdulkadir J., Feleke Y., Berg JP, Falch JA, Odegaard OR Absence of the factor V Leiden mutation in Ethiopians. Thromb Res. 1997 ; 86: 181-182.
9. Arnutti P., Nathalang O., Cowawintaweewat S., Prayoonwiwat W., Choovichian P. Factor V Leiden and prothrombin G20210 mutations in Thai patients awaiting kidney transplant. Southeast Asian J Trop Med Public Health. 2002 ; 33: 869-871.
10. Kim TW, Kim WK, Lee JH, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep venous thrombosis. J Korean Med Sci. 1998 ; 13: 587-590.
11. Lu Y., Zhao Y., Liu G., et al. Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb Res. 2002 ; 106: 7-12.
12. Irani-Hakime N., Tamim H., Kreidy R., Almawi WY The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol. 2000 ; 65: 45-49.
13. Tamim H., Finan RR, Almawi WY Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost. 2002 ; 88: 691-692.
14. Akar N., Akar E., Dalgin G., et al. Frequency of factor V 1691 G-A mutation in Turkish population. Thromb Haemost. 1997 ; 78: 1527.
15. Angelopoulou K., Nicolaides A., Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost. 2000 ; 6: 104-107.
16. Italian Study Group. Atherosclerosis, Thrombosis, and Vascular Biology. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infraction at a young age. Circulation. 2003 ; 107: 1117-1122.
17. Lopaciuk S., Bykowska K., Kwiecinski H., et al. Factor V Leiden, prothombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost. 2001 ; 7: 346-350.
18. Coen D., Zadro R., Honovic L., Banfic L., Stavljenic Rukavina A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001 ; 42: 488-492.
19. Aznar J., Vaya A., Estelles A., et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000 ; 85: 1271-1276.
20. Brown K., Luddington R., Baglin T. Effect of the MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998 ; 103: 42-44.
21. Brugada R., Marian AJ A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infraction. Atherosclerosis. 1997 ; 128: 107-112.
22. BrattstrOüm MD, Wilcken DEL, Öhrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the results of a meta-analysis. Circulation. 1998 ; 98: 2520-2526.
23. Fletcher O., Kessling AM MTHFR association with artheriosclerotic vascular disease. Hum Genet. 1998 ; 103: 11-21.
24. Benabadji M., Chamla MC Les groupes sanguins ABO et rhÁsus des algÁriens. Anthropologie. 1971 ; 75: 427-442.
25. Bosch E., Calafell F., Perez-Lezaun A., Comas D., Mateu F., Bertranpetit J. Population history of North Africa: evidence from classical genetic markers. Hum Biol. 1997 ; 69: 295-311.
26. Franco RF, Araujo AG, Guerreiro JF, Elion J., Zago MA Analysis of 677Cĝ†'T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost. 1998 ; 79: 119-121.
27. Stevenson RE, Schwartz CE, Du YZ, Adams MJ Jr. Differences in methylenetetrahydrofolate reductase genotype frequencies between Whites and Blacks. Am J Hum Genet. 1997 ; 60: 229-230.
28. Arruda VR, Siqueira LH, Goncalves MS, et al. Prevalence of the mutation 677Cĝ†'T in the methylenetetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet. 1998 ; 78: 332-335.
29. Camacho-Vanegas O., Giusti B., Restrepo Fernandez CM, Abbate R., Pepe G. Frequency of factor V (FV) Leiden and C677T methylenetetrahydrofolate reductase (MTHFR) mutations in Colombians. Thromb Haemost. 1998 ; 79: 883-884.
30. de Franchis R., Mancini FP, DgsAngelo A., et al. Elevated total plasma homocysteine and 677Cĝ†'T mutation of the 5,10- methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet. 1996 ; 59: 262-264.
31. Schneider JA, Rees DC, Liu YT, Clegg JB Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet. 1998 ; 62: 1253-1260.
32. Rosen E., Renbaum P., Heyd J., Levy-Lahad E. High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost. 1999 ; 82: 1768.
33. Guillen M., Corella D., Portoles O., Gonzalez JI, Mulet F., Saiz C. Prevalence of the methylenetetrahydrofolate reductase 677C>" xbd="538" xhg="517" ybd="2740" yhg="2718"/>T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol. 2001 ; 17: 255-261.
34. Jerbi Z., Abdennebi M., Douik H., et al. Etude du polymorphisme C677T du gène de la mÁthylène tÁtrahydrofolate rÁductase dans la population tunisienne. Ann Biol Clin. 2005 ; 63: 487-491.
35. Ameen G., Irani-Hakime N., Fawaz NA, Mahjoub T., Almawi WY An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T. J Thromb Haemost. 2005 ; 3: 2126-2127.
36. Pollak RD, Friedlander Y., Pollak A., Idelson M., Bejarano-Achache I., Blumenfeld A. Ethnic differences in frequency of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in healthy Israeli Populations. Genet Test. 2000 ; 3: 309-311.
37. Ivanova R., Astrinidis A., Djoulah S., et al. Mitochondrial DNA polymorphisms of a west Algerian population (Oran region). Biomed Pharmacother. 1999 ; 53: 386-392.
38. Helley D., Chafa O., Yaker NL, Reghis A., Fischer A-M. Prevalence of the prothrombin gene 20210A mutation in thrombophilic and healthy Algerian subjects. Thromb Haemost. 1999 ; 82: 1554-1555.
39. Ulu A., Elsobky E., Elsayed M., Yildiz Z., Tekin M., Akar N. Frequency of five thrombophilic polymorphisms in the Egyptian population. Turk J Hematol. 2006 ; 23: 100-103.
40. Gurgey A., Mesci L. The prevalence of factor V Leiden (1691G-A) mutation in Turkey. Turk J Pediatr. 1997 ; 39: 313-315.
41. Kabukcu S., Keskin N., Keskin A., Atalay E. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylenetetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey. Clin Appl Thromb Hemost. 2007 ; 13: 166-171.
42. Kurt C., Tanriverdi K., Kocak R. The frequency of factor V Leiden in southern Turkey. Ann Med Sci. 1999 ; 8: 56.
43. Vurkun M., Vural Ü., Demir M. The prevalence of activated protein C resistance and F V Leiden in healthy population of Edirne, Turkey. Turk J Hematol. 2002 ; 19: 287-291.
44. Awidi A., Shannak M., Bseiso A., et al. High prevalence of factor V Leiden in healthy Jordanian Arabs. Thromb Hemost. 1999 ; 81: 582-584.
45. Grandone E., Margaglione M., Colaizzo D., et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 1997 ; 77: 822-824.
46. Lucotte G., Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis. 2001 ; 27: 362.
47. Lefevre-Witier P., Aireche H., Benabadji M., et al. Genetic structure of Algerian populations. Am J Hum Biol. 2006 ; 18: 492-501.
48. Kluijtmans LAJ, van den Heuvel Lpwj, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996 ; 58: 35-41.
49. Kluijtmans LAJ, Den Heijer M., Reitsma PH, Heil SG, Blom HJ, Rosendaal FR Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. 1998 ; 79: 254-258.
50. Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005 ; 3: 392-399.
51. Torres JD, Cardona H., Alvarez L., et al. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population. Am J Hem. 2006 ; 81: 933-937.
52. Ma J., Stampfer MJ, Giovannucci E., et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997 ; 57: 1098-1102.
53. Rosenberg N., Murata M., Ikeda Y., et al. The frequent 5,10-Methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in Whites, Japanese, and Africans. Am J Hum Genet. 2002 ; 70: 758-762.
54. Chafa O., Reghis A., Aubert A., Fisher AM Prevalence of the FVQ506 (Factor V Leiden) mutation in the normal and thrombophilic Algerian population. Br J Haematol. 1997 ; 97: 688-689.